Switch theme
Sign up to access all valuation multiples
Cachet Pharmaceutical Co Ltd is a state-owned stock company. Its main business includes: Medicine supply to hospitals, wholesaling of biological products, medical instruments, and traditional Chinese medicines. The Company also involved in pharmaceutical logistics and retail pharmacy chain.
1997
n/a
Last FY Revenue $3.3B
Last FY EBITDA $110M
$646M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Cachet Pharmaceuticals achieved revenue of $3.3B and an EBITDA of $110M.
Cachet Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cachet Pharmaceuticals valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.3B | XXX | XXX | XXX |
| Gross Profit | XXX | $220M | XXX | XXX | XXX |
| Gross Margin | XXX | 7% | XXX | XXX | XXX |
| EBITDA | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 3% | XXX | XXX | XXX |
| EBIT | XXX | $94.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $22.3M | XXX | XXX | XXX |
| Net Margin | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | $55.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cachet Pharmaceuticals's stock price is CNY 14 (or $2).
Cachet Pharmaceuticals has current market cap of CNY 4.0B (or $554M), and EV of CNY 4.7B (or $646M).
See Cachet Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $646M | $554M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cachet Pharmaceuticals has market cap of $554M and EV of $646M.
Cachet Pharmaceuticals's trades at 0.2x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Cachet Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cachet Pharmaceuticals's P/E ratio is not available.
See valuation multiples for Cachet Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $554M | XXX | $554M | XXX | XXX | XXX |
| EV (current) | $646M | XXX | $646M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 6.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 24.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 28.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCachet Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Cachet Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cachet Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cachet Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cachet Pharmaceuticals acquired XXX companies to date.
Last acquisition by Cachet Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Cachet Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cachet Pharmaceuticals founded? | Cachet Pharmaceuticals was founded in 1997. |
| Where is Cachet Pharmaceuticals headquartered? | Cachet Pharmaceuticals is headquartered in China. |
| Is Cachet Pharmaceuticals publicy listed? | Yes, Cachet Pharmaceuticals is a public company listed on SHE. |
| What is the stock symbol of Cachet Pharmaceuticals? | Cachet Pharmaceuticals trades under 002462 ticker. |
| When did Cachet Pharmaceuticals go public? | Cachet Pharmaceuticals went public in 2010. |
| Who are competitors of Cachet Pharmaceuticals? | Similar companies to Cachet Pharmaceuticals include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Cachet Pharmaceuticals? | Cachet Pharmaceuticals's current market cap is $554M |
| Is Cachet Pharmaceuticals profitable? | Yes, Cachet Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
